Identifying molecules in the blood associated with long term healing problems in long bone fractures

Submission date	Recruitment status	Prospectively registered
05/04/2020	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
04/05/2020	Completed	[X] Results
Last Edited	Condition category	Individual participant data
08/06/2020	Musculoskeletal Diseases	

Plain English summary of protocol

Background and study aims

Some broken bones do not heal even when they get the best surgical or nonsurgical treatment. In some cases, certain risk factors make it more likely that a bone will fail to heal. When a broken bone fails to heal it is called a "nonunion." Incomplete fracture healing may lead to chronic nonunion, thus determining fracture healing is the basic issue in clinical treatment. However, there are no validated molecules in the blood (biomarkers) for p chronic nonunion. In this study, bioinformatics analysis combined with the experimental verification strategy was used to identify blood biomarkers for chronic nonunion.

Who can participate?

Patients diagnosed with open fractures of long bone and defined non-union.

What does the study involve?

Participants will provide a single blood sample for analysis.

What are the possible benefits and risks of participating? None explaected.

Where is the study run from? Xuanwu Hospital of Capital Medical University (China)

When is the study starting and how long is it expected to run for? August 2018 to October 2019

Who is funding the study? Investigator initiated and funded

Who is the main contact? Dr Limin Liu xwllm2019@sina.com

Contact information

Type(s)

Scientific

Contact name

Dr Limin Liu

ORCID ID

http://orcid.org/0000-0001-9167-9079

Contact details

Xuanwu Hospital of the Capital Medical University Changchun Street No.45 Beijing China 100053 +86-010-8319-8277 xwllm2019@sina.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

Bioinformatic analysis and experimental identification of blood biomarkers for chronic nonunion

Study objectives

Incomplete fracture healing may lead to chronic nonunion, thus determining fracture healing is the basic issue in clinical treatment. However, there were no validated early diagnose biomarkers for assessing chronic nonunion. In this study, bioinformatics analysis combined with the experimental verification strategy was used to identify blood biomarkers for chronic nonunion.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 13/07/2018, Ethics Committee of Xuanwu Hospital, Capital Medical University (Chuangchun Street No.45, Beijing, China, 100053; +86-010-8319-9270; xwkyethics@163.com), ref: XW-2018-135.

Study design

Observational

Primary study design

Observational

Secondary study design

Ecological study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Nonunion of open fractures of long bone

Interventions

Patients admitted to the Department of Orthopedics of Xuanwu Hospital between August 2018 and July 2019, are enrolled in this study. The group is categorized into the Healed and Nonunion groups, according to the FDA diagnostic criteria amendment. The FDA defines nonunion as a fractured bone that has not completely healed within 9 months following injury and without signs of healing for at least 3 months.

In this study, 9 months was chosen as the time point to define the nonunion.

Bioinformatics analysis combined with the experimental verification strategy was used to identify blood biomarkers for chronic nonunion. First, chronic nonunion differential expressed genes were identified by microarray data analysis. Second, Dipsaci Radix (DR), traditional Chinese medicine for fracture treatment, was used to screen the target genes. Third, the drug-compound-target-disease network was determined, and the biomarker genes were obtained. Finally, the potential blood biomarkers were verified by ELISA and qPCR methods.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Dipsaci Radix

Primary outcome measure

Biomarkers verified by ELISA and qPCR methods from a blood sample taken at a single time point

Secondary outcome measures

None

Overall study start date

01/05/2018

Completion date

31/10/2019

Eligibility

Key inclusion criteria

Patients diagnosed with open fractures of long bone and defined nonunion

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

100

Total final enrolment

55

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

01/08/2018

Date of final enrolment

31/07/2019

Locations

Countries of recruitment

China

Study participating centre Xuanwu Hospital of Capital Medical University Changchun Street No.45

Beijing

Sponsor information

Organisation

Xuan Wu Hospital of the Capital Medical University

Sponsor details

Changchun Street No.45 Beijing China 100053 +86-138-1051-7806 edmond pku@163.com

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/00k7r7f88

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

01/08/2020

Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication

IPD sharing plan summary

Other

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Results articleresults05/06/202008/06/2020YesNo